Fluoxetine and Nortriptyline Co-Administration
Fluoxetine and nortriptyline should NOT be routinely co-administered due to severe drug-drug interactions that can result in 2-11 fold increases in nortriptyline plasma levels, leading to potentially life-threatening tricyclic toxicity. 12
Critical Drug Interaction Mechanism
Fluoxetine is a potent CYP2D6 inhibitor that dramatically impairs nortriptyline metabolism. The FDA label explicitly warns that "greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, have been observed when fluoxetine has been administered in combination with these agents." 1 Research demonstrates even more severe interactions, with nortriptyline levels increasing 2-11 times at steady state when combined with fluoxetine. 2
This interaction creates a phenocopy effect where fluoxetine converts normal CYP2D6 metabolizers into functional poor metabolizers. At therapeutic doses of 20 mg/day, fluoxetine converts approximately 43% of normal metabolizers to poor metabolizer status. 3
If Co-Administration Is Absolutely Necessary
If clinical circumstances mandate combining these medications (which should be rare):
- Reduce nortriptyline dose by 50-75% when adding fluoxetine 41
- Obtain baseline nortriptyline plasma levels before adding fluoxetine
- Monitor therapeutic drug levels closely - target nortriptyline levels of 50-150 ng/mL 5
- Watch for anticholinergic toxicity: severe dry mouth, urinary retention, blurred vision, confusion (especially in elderly), cardiac conduction abnormalities 1
- Monitor ECG for QT prolongation and cardiac conduction abnormalities
- Be alert for serotonin syndrome (though uncommon with this specific combination) 6
Switching Between Medications
From Fluoxetine to Nortriptyline
Critical timing consideration: Fluoxetine has an exceptionally long half-life (4-16 days for its active metabolite norfluoxetine). 37
- Wait at least 5 weeks after stopping fluoxetine before starting nortriptyline at full dose 18
- This washout period allows fluoxetine's CYP2D6 inhibition to resolve
- If starting nortriptyline sooner, begin with 25-50% dose reduction and titrate slowly with therapeutic drug monitoring 41
- Do NOT assume fluoxetine auto-tapers safely - its metabolic inhibition persists well beyond plasma clearance
From Nortriptyline to Fluoxetine
- Taper nortriptyline gradually over 1-2 weeks (reduce by 25 mg every 3-7 days) 5
- Can initiate fluoxetine 20 mg once daily immediately after nortriptyline discontinuation 8
- No extended washout period required in this direction
- Monitor for discontinuation symptoms from nortriptyline (though less common than with SSRIs)
Clinical Context from Pharmacogenetic Guidelines
The interaction severity varies by CYP2D6 genotype 44:
- CYP2D6 poor metabolizers: Already have impaired nortriptyline metabolism - adding fluoxetine creates extreme toxicity risk. Avoid this combination entirely.
- CYP2D6 intermediate metabolizers: Require 40-60% nortriptyline dose reduction when combined with fluoxetine
- CYP2D6 normal metabolizers: Still require 50% dose reduction due to fluoxetine's inhibition
- CYP2D6 ultrarapid metabolizers: May tolerate combination better but still require dose reduction and monitoring
Safer Alternatives
Instead of combining fluoxetine + nortriptyline, consider:
- Switching to duloxetine or venlafaxine for dual serotonin-norepinephrine activity without the severe CYP2D6 interaction 59
- Using escitalopram or citalopram (minimal CYP2D6 effects) if an SSRI is needed alongside nortriptyline 6
- Augmenting with gabapentin or pregabalin for neuropathic pain rather than combining antidepressants 59
Common Pitfalls
- Underestimating interaction duration: Clinicians often restart nortriptyline too soon after fluoxetine, not accounting for the 5-week metabolite half-life
- Inadequate dose reduction: 25% reduction is insufficient; 50-75% reduction is required 41
- Failure to monitor levels: Blood level monitoring is essential, not optional, with this combination 210
- Missing early toxicity signs: Confusion in elderly patients may be dismissed as dementia rather than recognized as anticholinergic toxicity 1